Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.

Private insurance companies say U.S. patients aren't paying the true cost of expensive medications such as Wegovy and Zepbound, which can easily cost upwards of $1,000. Wegovy, the weight-loss ...

We recently published a list of 12 Best ADR Stocks To Invest In According to Analysts. In this article, we are going to take ...

The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...

The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...

Few companies garner as much reliable attention as Novo Nordisk (NYSE: NVO) does these days. Novo Nordisk is among the fastest-growing big pharma competitors, which makes it easy to formulate a long ...

But for a long time China’s people struggled to get hold of Wegovy because the country’s regulators had not approved it. Some ...

Health Canada has approved Novo Nordisk’s semaglutide injection, Wegovy, marking it as the first treatment in the country ...

Novo Nordisk shifts its recruitment focus to China, expanding operations to meet rising demand for Ozempic and Wegovy in the ...

Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or ...

The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.

A new Biden administration proposal could allow millions of Americans with obesity to access weight-loss drugs like Wegovy ...